ArticleQuantitative imaging in medicine and surgery2025
Epicardial adipose tissue provides incremental value in predicting major adverse cardiac events in systemic sclerosis patients without pulmonary arterial hypertension beyond traditional risk factors.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The relationship between epicardial adipose tissue and mortality in systemic sclerosis patients: 10-year follow-up results.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic sclerosis (SSc) patients face greater odds of developing cardiovascular disease. In this study, patient clinical characteristics, coronary artery calcium score (CACS) values, and epicardial fat volume (EFV) were analyzed to identify predictors of major adverse cardiovascular events (MACE) among SSc patients without pulmonary arterial hypertension (PAH). Methods: This study enrolled 202 SSc patients and 202 controls from the First Affiliated Hospital of Ningbo University. SSc patients were separated into two groups based on their MACE status. The relationship between EFV and MACE incidence was assessed with Kaplan-Meier curves and Cox proportional hazards regression models, calculating hazard ratios (HRs) and 95% confidence intervals (CIs). Discrimination efficiency was evaluated based on global chi-square, concordance index (C-index), net reclassification index (NRI), and integrated discrimination improvement (IDI) index results. The incremental value of EFV as a predictor of MACE incidence was analyzed among these SSc patients. Results: SSc patients presented with higher CACS values relative to controls {33.5 [interquartile range (IQR), 0-128.5] Conclusions: High EFV levels are independently associated with MACE risk among SSc patients, with poorer prognostic outcomes being evident among patients with SSc even if they were unaffected by PAH. The introduction of EFV offers incremental utility over traditional risk factors alone for the prediction of MACE incidence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.